Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KYNMOBI vs HYRNUO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Apomorphine is a non-ergoline dopamine receptor agonist with high affinity for D4 and moderate affinity for D2, D3, D5, and D1 receptors. It also has affinity for serotonergic (5-HT1A, 5-HT2A, 5-HT2B) and adrenergic (α1, α2) receptors. It improves motor function in Parkinson disease by stimulating striatal dopamine receptors.
(E)-2-(((2-(6,7-dimethoxyquinazolin-4-ylamino)phenyl)thio)methyl)-4-methyl-2H-pyrazolo[1,5-a]pyrazin-3(5H)-one is a selective inhibitor of fibroblast growth factor receptor (FGFR) 1, 2, 3, and 4. It binds to the ATP-binding site of FGFR kinases, blocking downstream signaling pathways, including RAS-MAPK-ERK and PI3K-AKT, thereby inhibiting tumor cell proliferation and angiogenesis.
Treatment of hypomobility, off episodes, and end-of-dose wearing-off in patients with advanced Parkinson disease,Off-label: Treatment of erectile dysfunction
Treatment of adult patients with previously treated, unresectable locally advanced or metastatic urothelial carcinoma (UC) with FGFR3 genetic alterations,Treatment of adult patients with unresectable locally advanced or metastatic cholangiocarcinoma (CCA) with FGFR2 gene fusions or other rearrangements
Sublingual film: 10 mg, 15 mg, 20 mg, 25 mg, or 30 mg as a single dose for acute off episodes; may repeat once within 4 hours if inadequate response; maximum 30 mg per dose and 3 doses per day.
100 mg orally once daily
The terminal elimination half-life of apomorphine is approximately 40 minutes. This short half-life necessitates continuous administration via subcutaneous infusion for sustained clinical effect.
Terminal elimination half-life is 12-15 hours in adults with normal renal function, supporting twice-daily dosing.
Extensively metabolized in the liver by glucuronidation via UGT1A1 and UGT2B7; also undergoes sulfation. N-demethylation via CYP1A2 and CYP3A4 may occur. No active metabolites identified.
Primarily metabolized by CYP2C9 and CYP3A4; minor contributions from CYP2C19 and CYP2D6. Forms active metabolites M1 (desmethyl) and M2 (N-oxide).
Apomorphine is predominantly metabolized in the liver. Renal excretion accounts for approximately 80% of the dose, with 10% excreted as unchanged drug and 70% as metabolites. Biliary/fecal excretion accounts for the remaining 20%.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30% (including metabolites), with the remainder eliminated via minor metabolic pathways.
Apomorphine is approximately 90% bound to plasma proteins, primarily albumin.
98% bound primarily to albumin.
The volume of distribution is approximately 200 L (about 2.9 L/kg for a 70 kg individual), indicating extensive tissue distribution.
0.3-0.4 L/kg, indicating distribution into total body water with limited tissue binding.
Bioavailability of apomorphine is low and variable after oral administration (<5%). Subcutaneous administration provides 100% bioavailability. Sublingual film (KYNMOBI) has a bioavailability of approximately 18% relative to subcutaneous injection.
Oral: 85% (fasting); 60% with high-fat meal (reduced absorption).
No specific dose adjustment provided; use caution in severe renal impairment (Cr Cl <30 m L/min) as data limited.
GFR ≥60 m L/min: No adjustment. GFR 30-59: 50 mg once daily. GFR <30: Not recommended.
No specific dose adjustment provided; use caution in Child-Pugh Class C as data limited.
Child-Pugh A: No adjustment. Child-Pugh B: 50 mg once daily. Child-Pugh C: Not recommended.
Safety and effectiveness in pediatric patients have not been established.
Not established for patients under 18 years.
No specific geriatric dose adjustment; pharmacokinetics similar to younger adults; monitor for hypotension and hallucinations.
No specific dose adjustment; monitor renal function and consider age-related decline.
KYNMOBI can cause serious adverse reactions, including severe nausea and vomiting, symptomatic orthostatic hypotension (particularly with concomitant antihypertensives), syncope, QT prolongation, and hallucinations/psychosis. It should not be used with serotonergic drugs due to risk of serotonin syndrome.
None
Orthostatic hypotension/syncope; nausea/vomiting (pretreat with antiemetic); hallucinations/psychosis; impulse control disorders; dyskinesias; coronary and cerebral ischemia; QT prolongation; priapism; somnolence/sudden sleep onset; falls; cardiac valvulopathy (due to ergot-like activity); potential for abuse (dopaminergic dysregulation syndrome).
Retinal pigment epithelial detachment (RPED) and other visual disturbances: conduct ophthalmic examinations prior to and during treatment,Hyperphosphatemia: monitor serum phosphate levels and manage with phosphate-lowering therapy or dose modification,Non-healing corneal ulcers: requires ophthalmologic evaluation,Embryo-fetal toxicity: can cause fetal harm; advise effective contraception
Concomitant use with serotonergic drugs (e.g., SSRIs, SNRIs, MAOIs, triptans) due to risk of serotonin syndrome; severe hepatic impairment; history of QT prolongation or concomitant QT-prolonging drugs; hypersensitivity to apomorphine or its components; use of 5-HT3 antagonists (e.g., ondansetron) for antiemesis (risk of profound hypotension).
Concurrent use with strong CYP2C9 or CYP3A4 inducers,Pregnancy and lactation
No specific food interactions are reported; however, administer on an empty stomach or at least 30 minutes before or after meals to optimize absorption. Avoid grapefruit juice as it may increase apomorphine levels. Alcohol should be avoided due to additive sedative and hypotensive effects.
No specific food interactions. Grapefruit juice does not significantly affect HYRNUO metabolism. Maintain consistent vitamin K intake if on warfarin; not applicable to HYRNUO. Alcohol may increase bleeding risk; advise moderation.
Apomorphine has not been studied in pregnant women. In animal studies, apomorphine was not teratogenic in rats or rabbits at doses up to 10 mg/kg/day (approximately 6 and 12 times the maximum human dose, respectively, on a mg/m² basis). No fetal malformations were observed. However, embryolethality and decreased fetal body weight occurred at maternally toxic doses in rabbits. Use during pregnancy only if potential benefit justifies potential risk to the fetus; first trimester risks are unknown.
HYRNUO is contraindicated in pregnancy due to demonstrated teratogenicity in animal studies and limited human data. First trimester exposure is associated with major congenital malformations including neural tube defects and cardiovascular anomalies. Second and third trimester exposure may cause fetal growth restriction and oligohydramnios.
It is not known whether apomorphine is excreted in human milk. No data on M/P ratio. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
No data available on excretion into breast milk or effects on the breastfed infant. M/P ratio unknown. Due to potential for serious adverse reactions, breastfeeding is not recommended during treatment and for at least 2 weeks after the last dose.
Pharmacokinetic changes during pregnancy may alter apomorphine clearance, although specific data are lacking. No dosing adjustment studies have been conducted. Use caution and monitor clinical response; dose adjustment may be necessary based on efficacy and tolerability, but no standard recommendation exists.
No established safe dose in pregnancy. Drug should not be used. If accidental exposure occurs, pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) may require dose adjustment, but no specific recommendations exist.
KYNMOBI (apomorphine sublingual film) is a rapid-onset, non-ergoline dopamine agonist for acute, intermittent treatment of OFF episodes in Parkinson disease. Onset of action occurs within 15-30 minutes. Administer film under the tongue and allow to dissolve completely; do not swallow saliva until dissolved. Nausea and vomiting are common pre-treatment with an antiemetic (e.g., trimethobenzamide) for at least 2 days prior. Monitor for hypotension, syncope, and QT prolongation. Avoid use with 5-HT3 antagonists (e.g., ondansetron) due to risk of profound hypotension. Do not use with apomorphine injection as it may lead to cumulative adverse effects.
HYRNUO is a novel oral anticoagulant with high specificity for factor Xa. Monitor renal function prior to initiation and periodically; adjust dose if Cr Cl <30 m L/min. No routine coagulation monitoring required. Reversal agent andexanet alfa is available for life-threatening bleeding. Avoid in patients with mechanical heart valves or moderate-to-severe mitral stenosis. Caution with dual antiplatelet therapy due to increased bleeding risk.
Place the film under your tongue and let it dissolve completely. Do not chew, swallow, or move the film with your tongue.,Do not eat or drink until the film has fully dissolved to ensure proper absorption.,Take KYNMOBI only at the first sign of an OFF episode to improve mobility.,You may experience nausea and vomiting; your doctor may prescribe an antiemetic to take before your first dose.,Avoid alcohol, as it may increase sedation and hypotension.,Do not drive or operate machinery until you know how KYNMOBI affects you, as it may cause dizziness, drowsiness, or sudden sleep onset.,Report any unusual urges (gambling, sexual, spending) to your doctor as these can occur with dopamine agonists.,Do not use this medicine more than 5 times per day or more often than every 2 hours.
Take HYRNUO exactly as prescribed, usually once daily with or without food.,Do not skip doses; if a dose is missed, take it as soon as remembered on the same day. Do not double the next dose.,Inform all healthcare providers that you are taking HYRNUO, especially before surgery or dental procedures.,Watch for signs of bleeding: unusual bruising, prolonged bleeding from cuts, pink/brown urine, red/black stools, coughing up blood, or vomiting blood.,Avoid aspirin, NSAIDs, or other blood thinners unless prescribed by your doctor.,Keep a list of all medications and supplements you take, as some may interact with HYRNUO.,Store at room temperature away from moisture and heat. Do not stop taking without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KYNMOBI vs HYRNUO, answered by our medical review team.
KYNMOBI is a Dopamine Agonist that works by Apomorphine is a non-ergoline dopamine receptor agonist with high affinity for D4 and moderate affinity for D2, D3, D5, and D1 receptors. It also has affinity for serotonergic (5-HT1A, 5-HT2A, 5-HT2B) and adrenergic (α1, α2) receptors. It improves motor function in Parkinson disease by stimulating striatal dopamine receptors.. HYRNUO is a Dopamine Agonist (Antiparkinsonian) that works by (E)-2-(((2-(6,7-dimethoxyquinazolin-4-ylamino)phenyl)thio)methyl)-4-methyl-2H-pyrazolo[1,5-a]pyrazin-3(5H)-one is a selective inhibitor of fibroblast growth factor receptor (FGFR) 1, 2, 3, and 4. It binds to the ATP-binding site of FGFR kinases, blocking downstream signaling pathways, including RAS-MAPK-ERK and PI3K-AKT, thereby inhibiting tumor cell proliferation and angiogenesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KYNMOBI and HYRNUO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KYNMOBI is: Sublingual film: 10 mg, 15 mg, 20 mg, 25 mg, or 30 mg as a single dose for acute off episodes; may repeat once within 4 hours if inadequate response; maximum 30 mg per dose and 3 doses per day.. The standard adult dose of HYRNUO is: 100 mg orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KYNMOBI and HYRNUO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KYNMOBI is classified as Category C. Apomorphine has not been studied in pregnant women. In animal studies, apomorphine was not teratogenic in rats or rabbits at doses up to 10 mg/kg/day (approximately 6 and 12 times . HYRNUO is classified as Category C. HYRNUO is contraindicated in pregnancy due to demonstrated teratogenicity in animal studies and limited human data. First trimester exposure is associated with major congenital mal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.